- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02509130
MISSION Severe Asthma Modern Innovative Solutions to Improve Outcomes in Severe Asthma. (MISSION)
MISSION Severe Asthma: Modern Innovative Solutions to Improve Outcomes in Severe Asthma. A Mixed Methods Observational Comparison of Clinical Outcomes in MISSION Versus Current Care Delivery.
Study Overview
Status
Conditions
Detailed Description
Purpose and design
The purpose of the study is to evaluate in detail the clinical and health economic outcomes from the MISSION project. The MISSION clinics combined a new way of delivering asthma care along with actively case finding patients who were not already known to specialist services but who had uncontrolled or at risk asthma.
The aim of the study is to compare the MISSION clinic model outcomes to current clinic model outcomes as well as performing qualitative interviews with patients who attended and staff who took part in the project.The research study was developed by a team from Portsmouth Hospital Trust and the University of Portsmouth including a research fellow, consultant and Professor, research methodologist, qualitative senior lecturer and independent statistician. A patient adviser also reviewed the lay summary and patient information sheets. The study undergoes independent review by another clinician as part of the sponsor process.
The study is also part of an MD project for the University of Portsmouth.
Design:
This is a mixed methods study.
A quantitative analysis of data from patients who attended the MISSION Rapid Access Asthma Clinics (RAAC), patients who attended the MISSION Severe Asthma Assessment Clinics (SAAC), patients who were invited to the RAAC but did not attend and patients who have been referred by their GP to the severe asthma clinic during the same time MISSION was running. The data analysis will include asthma control, hospital admissions, GP appointments, related medical conditions,medications, investigations and assessments done and time between appointments.
A qualitative study will be conducted using telephone interviews with patients who attended the SAAC and health care professionals who took part in the MISSION clinics.
The aim is to recruit:
- 44 MISSION patients (of whom 20 attended both the RAAC and the SAAC),
- 132 patients who were invited to MISSION RAAC but did not attend
- 20 patients referred to the severe asthma clinic at the hospital
- 20 health care professionals who took part in the MISSION clinics
Methodology:
Participants will be approached for consent by post. They will be given time to read the information and return the consent form to the study team. They will be given a contact number to discuss any questions.
Once a participant has consented to the quantitative study there is no further study procedures for the participant. Participants will be asked for consent to collect data from their GP and hospital records for the study. This will be entered onto a form (CRF) against a study number and then into a password protected study database held on a secure server at Portsmouth Hospitals NHS Trust. This data will then be analysed by a statistician and research fellow.
Participants for qualitative interview will have an interview over the telephone lasting 45 minutes to one hour. This will be recorded and transcribed. The participant will be given the transcript to read and correct. The transcripts will then be analysed looking for themes.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Hampshire
-
Portsmouth, Hampshire, United Kingdom, PO6 3LY
- Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Participants with uncontrolled or potentially severe asthma identified from GP records by the MISSION team and new referrals to an asthma specialist clinic at Queen Alexandra Hospital between May and August 2014.
Study participants for qualitative interview will be recruited from patients who attended MISSION SAAC days and staff who attended MISSION RAAC or SAAC days.
Description
Inclusion Criteria:
- Male or Female, aged 18 years or above.
- Is in one of the following population groups:
- Attended the MISSION RAAC or
- Attended the MISSION SAAC or
- Identified as uncontrolled asthma by record searches and invited to MISSION RAAC but did not attend - 'primary care patients' or
- Has been referred to the specialist asthma clinic at Queen Alexandra Hospital - 'outpatient severe asthma patients' or
- Attended the MISSION RAAC or SAAC as a health care professional
- Participant is willing and able to give informed consent for participation in the study.
Exclusion Criteria:
- The patient is unable or unwilling to give consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients who attended RAAC/SAAC.
Patients who have previously attended the Rapid Access Asthma Clinic (RAAC) will be approached for the quantitative study.
Patients who went onto the attend the Severe Asthma Assessment Clinics (SAAC) will also be approached for the quantitative and qualitive parts of the study.
|
Patients eligible for RAAC, but DNA'd
Patients identified by the GP search, who did not attend the previous MISSION clinics will be approached to participate in the quantitative part of the study.
|
Asthma Outpatients
Patients who are attending outpatient clinics as new referrals will be approached to participate in the quantitative part of the study.
|
Healthcare Professionals
Healthcare professionals who performed the MISSION RAAC or SAAC will be approached for qualitative interview part of the study only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Asthma control as measured by exacerbation frequency for all patients
Time Frame: 6 months
|
The primary endpoint is asthma control as measured by exacerbation frequency (defined as deterioration in symptoms requiring ≥30mg prednisolone or equivalent for ≥3 days) for all patients
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short acting bronchodilator (SABA) use
Time Frame: 6 months
|
Short acting bronchodilator (SABA) use measured by number of inhalers prescribed in 6 months pre and post MISSION SAAC, RAAC or outpatient clinic.
|
6 months
|
Exacerbation frequency
Time Frame: 6 months
|
Exacerbation frequency (defined as deterioration in symptoms requiring ≥30mg prednisolone or equivalent for ≥3 days) in 6 months pre and post MISSION SAAC, RAAC or outpatient clinic.
|
6 months
|
Health care usage costs for asthma and number of contacts
Time Frame: 6 months
|
Health care usage costs for asthma and number of contacts (GP visits, Emergency Department (ED) or out of hour attendances (OOH), hospital admissions, emergency GP visits) over 6 months pre and post MISSION or outpatient clinic.
|
6 months
|
Assessment of co-morbidity
Time Frame: 6 months
|
Assessment of comorbidity (rhinosinusitis, anxiety and depression, dysfunctional breathing, gastro oesophageal reflux and obstructive sleep apnoea) and method of assessment for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Assessment of inhaler technique and recommendations for inhaler devices.
Time Frame: 6 months
|
Assessment of inhaler technique and recommendations for inhaler devices for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Smoking cessation advice.
Time Frame: 6 months
|
Smoking cessation advice for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Investigations performed in secondary care
Time Frame: 6 months
|
Investigations performed during 6 months in secondary care e.g.
full lung function, sputum induction, High-Resolution Computed Tomography (HRCT) chest for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Time from GP referral to 1st clinic visit
Time Frame: 6 months
|
Time from GP referral to 1st clinic visit in secondary care for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Time between 1st and 2nd visit
Time Frame: 6 months
|
Time between 1st and 2nd visit in secondary care for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Time to appointment with other specialists
Time Frame: 6 months
|
Time to appoint with other specialists for asthma related comorbidity where indicated, e.g.
dietician, Ear, Nose & Throat (ENT), physiotherapists, psychologist, CT imaging for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Fractional Exhaled Nitric Oxide (FeNO) Assessment
Time Frame: 6 months
|
Assessment of eosinophilic airways inflammation by FeNO for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Frequency of non-attendance
Time Frame: 6 months
|
The frequency of non-attendance at clinic for MISSION SAAC patients and outpatient severe asthma clinic patients
|
6 months
|
Severity of co-morbidities
Time Frame: 6 months
|
Severity of co-morbidities for MISSION RAAC patients
|
6 months
|
Frequency of co-morbidities
Time Frame: 6 months
|
Frequency of co-morbidities for MISSION RAAC patients
|
6 months
|
Frequency & type of allergy
Time Frame: 6 months
|
Frequency & type of allergy for MISSION RAAC patients
|
6 months
|
Measurement of exhaled nitric oxide
Time Frame: 6 months
|
Measurement of exhaled nitric oxide for MISSION RAAC patients
|
6 months
|
Measurement & variation of lung function (Single
Time Frame: 6 months
|
Composite measurement & variation of lung function for MISSION RAAC patients
|
6 months
|
Frequency and type of additional asthma control medication.
Time Frame: 6 months
|
Frequency and type of additional asthma control medication for MISSION RAAC patients
|
6 months
|
Quality of life
Time Frame: 6 months
|
Quality of life as assessed by the Asthma Quality of Life Questionnaire (AQLQ).
|
6 months
|
Disease control
Time Frame: 6 months
|
Disease control as assessed by the Asthma Control Questionnaire (ACQ)
|
6 months
|
Number of Forced Expiratory Volume at one second (FEV1) / Forced Vital Capacity (FVC) measurements
Time Frame: 6 months
|
Number of patients having measurements of FEV1/FVC as a proxy for asthma control and severity in the MISSION RAAC patient and primary care patients
|
6 months
|
Prescription of SABA's
Time Frame: 6 months previous
|
Prescription of Short Acting Bronchodilators (SABAs) during last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
6 months previous
|
Prescription of SABA's
Time Frame: Baseline
|
Prescription of Short Acting Bronchodilators (SABAs) during last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
Baseline
|
Prescription of SABA's
Time Frame: 6 months
|
Prescription of Short Acting Bronchodilators (SABAs) during last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
6 months
|
Exacerbation rates
Time Frame: 6 months previous
|
Exacerbation rates (defined as deterioration in symptoms requiring ≥30mg prednisolone or equivalent for ≥3 days) during the last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
6 months previous
|
Exacerbation rates
Time Frame: Baseline
|
Exacerbation rates (defined as deterioration in symptoms requiring ≥30mg prednisolone or equivalent for ≥3 days) during the last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
Baseline
|
Exacerbation rates
Time Frame: 6 months
|
Exacerbation rates (defined as deterioration in symptoms requiring ≥30mg prednisolone or equivalent for ≥3 days) during the last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
6 months
|
ED attendances during the last 6 months
Time Frame: 6 months previous
|
Emergency Department (ED) attendances during the last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
6 months previous
|
Out Of Hours (OOH) contacts during the last 6 months
Time Frame: 6 months previous
|
Out Of Hours (OOH) contacts during the last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
6 months previous
|
Hospital admissions during the last 6 months
Time Frame: 6 months previous
|
Emergency Department (ED) attendances, Out Of Hours (OOH) contacts and hospital admissions during the last 6 months at baseline and 6 months for MISSION RAAC and primary care patients.
|
6 months previous
|
ED attendances at baseline
Time Frame: Baseline
|
Emergency Department (ED) attendances at baseline for MISSION RAAC and primary care patients.
|
Baseline
|
OOH contacts at baseline
Time Frame: Baseline
|
Out Of Hours (OOH) contacts at baseline for MISSION RAAC and primary care patients.
|
Baseline
|
Hospital admissions at baseline
Time Frame: Baseline
|
Hospital admissions at baseline for MISSION RAAC and primary care patients.
|
Baseline
|
ED attendances at 6 months.
Time Frame: 6 months
|
Emergency Department (ED) attendances at 6 months for MISSION RAAC and primary care patients.
|
6 months
|
Out Of Hours (OOH) contacts at 6 months
Time Frame: 6 months
|
Out Of Hours (OOH) contacts at 6 months for MISSION RAAC and primary care patients.
|
6 months
|
Hospital admissions during at 6 months
Time Frame: 6 months
|
Hospital admissions during at 6 months for MISSION RAAC and primary care patients.
|
6 months
|
Inhaled steroid doses and usage
Time Frame: 6 months
|
Inhaled steroid doses and usage for MISSION RAAC and primary care patients.
|
6 months
|
sensitivity and specificity of the Primary Care Information Services (PRIMIS) Asthma Audit Tool
Time Frame: 6 months
|
The sensitivity and specificity of the PRIMIS Asthma Audit Tool in identifying the patients compared to gold standard specialist assessment and interrogation of primary care records for MISSION RAAC and primary care patients.
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Professor Anoop J Chauhan, Portsmouth Hospitals NHS Trust
Publications and helpful links
General Publications
- Hoddinott P, Pill R. Qualitative research interviewing by general practitioners. A personal view of the opportunities and pitfalls. Fam Pract. 1997 Aug;14(4):307-12. doi: 10.1093/fampra/14.4.307.
- Hoddinott P, Pill R. A review of recently published qualitative research in general practice. More methodological questions than answers? Fam Pract. 1997 Aug;14(4):313-9. doi: 10.1093/fampra/14.4.313.
- Bulpitt H, Martin PJ. Who am I and what am I doing? Becoming a qualitative research interviewer. Nurse Res. 2010;17(3):7-16. doi: 10.7748/nr2010.04.17.3.7.c7741.
- Richards H, Emslie C. The 'doctor' or the 'girl from the University'? Considering the influence of professional roles on qualitative interviewing. Fam Pract. 2000 Feb;17(1):71-5. doi: 10.1093/fampra/17.1.71.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHT/2015/15
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia